BAYZED HEALTH (02609) announced that on May 18, 2026, its wholly-owned subsidiary, Baize Medical Investment Group Co., Ltd., signed a strategic cooperation agreement with Meinian Onehealth Industry (Group) Co., Ltd. ("Meinian Onehealth"), a subsidiary of Meinian Onehealth Industry Holding Co., Ltd. (Shenzhen Stock Exchange: 002044.SZ). The agreement aims to jointly advance the construction of a full-cycle health management service system integrating "prevention, screening, diagnosis, treatment, and rehabilitation" across the country, leveraging their respective strengths.
According to the strategic cooperation agreement, the parties intend to engage in in-depth collaboration in the following areas: - Brand and Business Synergy: "Baize Early Screening" brand zones will be established within eligible physical examination centers under Meinian Onehealth, and co-branded health checkup packages will be jointly launched. These packages will include services such as painless gastrointestinal endoscopy, liver elasticity testing, and remote expert interpretation, aiming to enhance early detection capabilities for major diseases. - Patient Referral and Service Linkage: For clients identified with suspected lesions during Meinian Onehealth's examinations or those requiring multidisciplinary team (MDT) consultations, and with the client's informed consent, their health information will be prioritized for referral through compliant channels to designated medical institutions within the group, providing access to green channels and MDT consultation services. - Data Interconnection and Platform Collaboration: The parties will explore compliant mechanisms for sharing health data, strictly adhering to laws and regulations including the Personal Information Protection Law of the People's Republic of China and obtaining separate, explicit authorization from clients. This collaboration aims to support precise health management and continuous service delivery. - Medical Resource Sharing: An expert resource collaboration mechanism will be established to promote the efficient allocation and coordinated service delivery of high-quality medical resources.
The board of directors considers this cooperation a significant milestone in implementing the group's eight-ring service system encompassing "prevention, screening, diagnosis, treatment, rehabilitation, management, linkage, and companionship." It is expected to strengthen the implementation capabilities of the "Hospital at Home" (H@H) service model. By integrating the group's professional expertise in precision oncology diagnosis and treatment, surgical therapy, and rehabilitation management with Meinian Onehealth's extensive physical examination network, rich health data resources, and broad customer base, both parties aim to jointly create a replicable and sustainable new ecosystem for health management.
Therefore, the board believes this cooperation aligns with the interests of the company and all shareholders. It is expected to expand the group's service coverage, enhance brand influence, and improve the accessibility of high-quality medical resources. Simultaneously, the cooperation is also anticipated to bring multiple benefits to Meinian Onehealth, including: extending its service chain from single physical examination report delivery to subsequent diagnosis, treatment, and rehabilitation management, thereby increasing customer retention; launching higher-value-added co-branded products to improve average customer spending and gross margin structure; establishing clear and professional expert referral channels to strengthen its authoritative image in the field of major disease prevention; and achieving the reuse of human resources during off-peak periods to optimize operational efficiency.
To the best of the directors' knowledge, information, and belief after making all reasonable inquiries, Meinian Onehealth and its ultimate beneficial owners are independent third parties with no connections to the company or its associates (as defined in the Hong Kong Stock Exchange Listing Rules). The signing of this strategic cooperation agreement does not constitute a discloseable transaction under Chapter 14 of the Listing Rules. Therefore, the company is not required to comply with the reporting, announcement, and independent shareholder approval provisions under the Listing Rules.
The board hereby emphasizes that the implementation of the strategic cooperation lays the foundation for establishing a long-term strategic partnership between the parties. However, such cooperation is subject to the execution of appropriate definitive agreements by both parties. The board further emphasizes that, as of the date of this announcement, no definitive agreements regarding any specific projects under the strategic cooperation have been signed by the parties or the company. Consequently, the strategic cooperation may or may not materialize. Should any specific project under the strategic cooperation be implemented, the company will comply with the relevant provisions of the Listing Rules and make further disclosures in due course in accordance with all applicable requirements.
Comments